12 results on '"Lavigne, Jean‐Philippe"'
Search Results
2. Diagnosis of brucellosis: Combining tests to improve performance.
- Author
-
Loubet, Paul, Magnan, Chloé, Salipante, Florian, Pastre, Théo, Keriel, Anne, O'Callaghan, David, Sotto, Albert, and Lavigne, Jean-Philippe
- Subjects
SERODIAGNOSIS ,ZOONOSES ,AGGLUTINATION tests ,RESOURCE-limited settings ,CONSCIOUSNESS raising ,BRUCELLA - Abstract
Introduction: Brucellosis, a zoonotic infectious disease caused by bacteria of the genus Brucella, remains a significant global health concern in many parts of the world. Traditional diagnostic methods, including serological tests, suffer from limitations, including low sensibility and high false-positive rates, emphasizing the need for improved diagnostic strategies. In this study, we aimed to optimize diagnostic accuracy by reevaluating serological tests and exploring novel diagnostic algorithms. Methods: A retrospective observational study was conducted using sera collected between June 2012 and June 2023 at the French National Reference Center for Brucella. Various serological tests, including Rose Bengal plate test (RBT), standard agglutination test (SAT), Brucellacapt, and ELISA for IgM and IgG, were performed. Different diagnostic algorithms were evaluated, combining RBT with SAT, Brucellacapt, and ELISA to enhance the performance of diagnostic tests. Results: Among 3587 sera analyzed, 148 were confirmed cases of human brucellosis. Individual serological tests exhibited good sensitivity and specificity but lacked diagnostic accuracy. However, combining RBT with SAT or Brucellacapt significantly improved diagnostic performance, with reduced false positives. The most promising results were observed when an algorithm was built combining RBT, Brucellacapt, and ELISA for IgM and IgG (a score value of 0.5 with 90.5% for sensitivity, 99.7% for specificity, 92.4% for PPV, and 99.6% for NPV). Conclusions: Serological tests remain crucial for brucellosis diagnosis, but their limitations necessitate innovative diagnostic approaches. Combining multiple serological tests in diagnostic algorithms shows promise in improving diagnostic accuracy. Efforts to refine diagnostic, strengthen surveillance, and raise awareness are essential for effective brucellosis control, particularly in resource-limited settings. Author summary: Brucellosis is a zoonotic infectious disease caused by bacteria of the genus Brucella. This disease remains a significant global health concern in many parts of the world. Traditional diagnostic methods include serological tests. However, these tests have major limitations due to their low sensibility and high false-positive rates. This poses a significant challenge in clinical practice, emphasizing the necessity for careful interpretation of test results and the development of more specific diagnostic tools. In this study, we assess the utility of traditional and easily accessible serological tests. Instead of using them individually, we decided to integrate the results of these multiple testing methods. We highlight the value of combining serological results into an algorithm to enhance the diagnosis of brucellosis and achieve greater overall accuracy in diagnosis. Efforts to streamline diagnostic, bolster surveillance, and increase awareness are essential for controlling brucellosis, particularly in resource-limited settings with a high disease burden. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus.
- Author
-
Jean-Pierre, Vincent, Sorlin, Pauline, Jeannot, Katy, Chiron, Raphaël, Lavigne, Jean-Philippe, Pantel, Alix, and Marchandin, Hélène
- Subjects
LITERATURE reviews ,ACHROMOBACTER ,TEST methods ,CEPHALOSPORINS ,SPECIES - Abstract
Background: Cefiderocol is a siderophore-conjugated cephalosporin increasingly used in the management of Achromobacter infections. Testing for cefiderocol susceptibility is challenging with distinct recommendations depending on the pathogens. Objectives: We evaluated the performance of commercial tests for testing cefiderocol susceptibility in the Achromobacter genus and reviewed the literature. Methods: Diffusion (disks, MIC gradient test strips [MTS], Liofilchem) and broth microdilution (BMD) methods (ComASP™, Liofilchem; UMIC
® , Bruker) were compared with the BMD reference method according to the EUCAST guidelines on 143 Achromobacter strains from 14 species with MIC50/90 of ≤ 0.015/0.5 mg/L. A literature search was conducted regardless of method or species. Results: None of the methods tested fulfilled an acceptable essential agreement (EA). MTS displayed the lowest EA (30.8%) after UMIC® (49%) and ComASP™ (76.9%). All methods achieved an acceptable bias, with MICs either underestimated using MTS (-1.3%) and ComASP™ (-14.2%) or overestimated with UMIC® (+ 9.1%). Inhibition zone diameters ranged from 6 to 38 mm (IZD50/90 =33/30 mm). UMIC® and ComASP™ failed to categorize one or the two cefiderocol-resistant strains of this study as resistant unlike the diffusion-based methods. The literature review highlighted distinct performance of the available methods according to pathogens and testing conditions. Conclusions: The use of MTS is discouraged for Achromobacter spp. Disk diffusion can be used to screen for susceptible strains by setting a threshold diameter of 30 mm. UMIC® and ComASP™ should not be used as the sole method but have to be systematically associated with disk diffusion to detect the yet rarely described cefiderocol-resistant Achromobacter sp. strains. Highlights: Performance of commercial methods are highly diverse and species-dependent. The use of MTS is discouraged due to low essential agreement. UMIC® and ComASP™ failed to detect one or the two cefiderocol-resistant strains. UMIC® or ComASP™ should not be used as the sole method for Achromobacter cefiderocol susceptibility testing. A threshold diameter of 30 mm is proposed for susceptible strain screening. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
4. A prospective multicentre evaluation of BioFire® Joint Infection Panel for the rapid microbiological documentation of acute arthritis
- Author
-
Gaillard, Tiphaine, primary, Dupieux-Chabert, Céline, additional, Roux, Anne-Laure, additional, Tessier, Eve, additional, Boutet-Dubois, Adeline, additional, Courboulès, Camille, additional, Corvec, Stéphane, additional, Bémer, Pascale, additional, Lavigne, Jean-Philippe, additional, El Sayed, Faten, additional, Marchandin, Hélène, additional, Munier, Clément, additional, Chanard, Emmanuel, additional, Gazzano, Vincent, additional, Loiez, Caroline, additional, and Laurent, Frédéric, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.
- Author
-
Jean-Pierre, Vincent, Sorlin, Pauline, Pantel, Alix, Chiron, Raphaël, Lavigne, Jean-Philippe, Jeannot, Katy, Marchandin, Hélène, Amara, Marlène, Cadot, Lucile, Dauwalder, Olivier, Degand, Nicolas, Demar, Magalie, Dupin, Clarisse, Fangous, Marie-Sarah, Franczak, Claire, Garnier, Fabien, Guiet, Pascal, Guinard, Jérôme, Hombrouck-Alet, Cécile, and Kaoula, Atika
- Subjects
ACHROMOBACTER ,BIOLOGICAL evolution ,MEROPENEM ,CYSTIC fibrosis ,IMMUNOCOMPROMISED patients ,DRUG resistance in microorganisms ,COLLECTIONS - Abstract
Background: Achromobacter spp. are opportunistic pathogens, mostly infecting immunocompromised patients and patients with cystic fibrosis (CF) and considered as difficult-to-treat pathogens due to both intrinsic resistance and the possibility of acquired antimicrobial resistance. Species identification remains challenging leading to imprecise descriptions of resistance in each taxon. Cefiderocol is a broad-spectrum siderophore cephalosporin increasingly used in the management of Achromobacter infections for which susceptibility data remain scarce. We aimed to describe the susceptibility to cefiderocol of a collection of Achromobacter strains encompassing different species and isolation sources from CF or non-CF (NCF) patients. Methods: We studied 230 Achromobacter strains (67 from CF, 163 from NCF patients) identified by nrdA gene-based analysis, with available susceptibility data for piperacillin–tazobactam, meropenem and trimethoprim–sulfamethoxazole. Minimal inhibitory concentrations (MICs) of cefiderocol were determined using the broth microdilution reference method according to EUCAST guidelines. Results: Strains belonged to 15 species. A. xylosoxidans represented the main species (71.3%). MICs ranged from ≤ 0.015 to 16 mg/L with MIC
50/90 of ≤ 0.015/0.5 mg/L overall and 0.125/2 mg/L against 27 (11.7%) meropenem-non-susceptible strains. Cefiderocol MICs were not related to CF/NCF origin or species although A. xylosoxidans MICs were statistically lower than those of other species considered as a whole. Considering the EUCAST non-species related breakpoint (2 mg/L), 228 strains (99.1%) were susceptible to cefiderocol. The two cefiderocol-resistant strains (A. xylosoxidans from CF patients) represented 3.7% of meropenem-non-susceptible strains and 12.5% of MDR strains. Conclusions: Cefiderocol exhibited excellent in vitro activity against a large collection of accurately identified Achromobacter strains, irrespective of species and origin. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
- Author
-
Bardol, Thomas, Dujon, Antoine M., Taly, Valerie, Dunyach-Remy, Catherine, Lavigne, Jean-Philippe, Costa-Silva, Bruno, Kurma, Keerthi, Eslami-S, Zahra, Cayrefourcq, Laure, Canivet, Cindy, Muscari, Fabrice, Bournet, Barbara, and Alix-Panabières, Catherine
- Subjects
EARLY detection of cancer ,BIOPSY ,CELL-free DNA ,CIRCULATING tumor DNA ,LIQUIDS ,PANCREATIC tumors ,ADRENAL insufficiency - Abstract
Background: Pancreatic cancer, predominantly characterized by ductal adenocarcinoma (PDAC) accounts for 90% of cases and is the fourth leading cause of cancer-related deaths globally. Its incidence is notably increasing. This poor prognosis is primarily due to late-stage diagnosis (approximately 70% to 80% of patients are diagnosed at an advanced stage), aggressive tumor biology, and low sensitivity to chemotherapy. Consequently, it is crucial to identify and develop a simple, feasible and reproducible blood-based signature (i.e., combination of biomarkers) for early detection of PDAC. Methods: The PANLIPSY study is a multi-center, non-interventional prospective clinical trial designed to achieve early detection of PDAC with high specificity and sensitivity, using a combinatorial approach in blood samples. These samples are collected from patients with resectable, borderline or locally advanced, and metastatic stage PDAC within the framework of the French Biological and Clinical Database for PDAC cohort (BACAP 2). All partners of the BACAP consortium are eligible to participate. The study will include 215 PDAC patients, plus 25 patients with benign pancreatic conditions from the PAncreatic Disease Cohort of TOuLouse (PACTOL) cohort, and 115 healthy controls, totaling 355 individuals. Circulating biomarkers will be collected in a total volume of 50 mL of blood, divided into one CellSave tube (10 mL), two CELL-FREE DNA BCT® preservative tubes (18 mL), and five EDTA tubes (22 mL in total). Samples preparation will adhere to the guidelines of the European Liquid Biopsy Society (ELBS). A unique feature of the study is the AI-based comparison of these complementary liquid biopsy biomarkers. Main end-points: i) to define a liquid biopsy signature that includes the most relevant circulating biomarkers, ii) to validate the multi-marker panel in an independent cohort of healthy controls and patients, with resectable PDAC, and iii) to establish a unique liquid biopsy biobank for PDAC study. Discussion: The PANLIPSY study is a unique prospective non-interventional clinical trial that brings together liquid biopsy experts. The aim is to develop a biological signature for the early detection of PDAC based on AI-assisted detection of circulating biomarkers in blood samples (CTCs, ctDNA, EVs, circulating immune system, circulating cell-free nucleosomes, proteins, and microbiota). Trial registration: ClinicalTrials.gov Identifier: NCT06128343 / NCT05824403. Registration dates: June 8,2023 and April 21, 2023. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Direct metagenomics investigation of non-surgical hard-to-heal wounds: a review.
- Author
-
Morsli, Madjid, Salipante, Florian, Magnan, Chloé, Dunyach-Remy, Catherine, Sotto, Albert, and Lavigne, Jean-Philippe
- Subjects
NUCLEOTIDE sequencing ,METAGENOMICS ,EPSTEIN-Barr virus ,COLONIZATION (Ecology) ,CHRONIC wounds & injuries ,FUNGAL colonies ,BACTERIOPHAGES - Abstract
Background: Non-surgical chronic wounds, including diabetes-related foot diseases (DRFD), pressure injuries (PIs) and venous leg ulcers (VLU), are common hard-to-heal wounds. Wound evolution partly depends on microbial colonisation or infection, which is often confused by clinicians, thereby hampering proper management. Current routine microbiology investigation of these wounds is based on in vitro culture, focusing only on a limited panel of the most frequently isolated bacteria, leaving a large part of the wound microbiome undocumented. Methods: A literature search was conducted on original studies published through October 2022 reporting metagenomic next generation sequencing (mNGS) of chronic wound samples. Studies were eligible for inclusion if they applied 16 S rRNA metagenomics or shotgun metagenomics for microbiome analysis or diagnosis. Case reports, prospective, or retrospective studies were included. However, review articles, animal studies, in vitro model optimisation, benchmarking, treatment optimisation studies, and non-clinical studies were excluded. Articles were identified in PubMed, Google Scholar, Web of Science, Microsoft Academic, Crossref and Semantic Scholar databases. Results: Of the 3,202 articles found in the initial search, 2,336 articles were removed after deduplication and 834 articles following title and abstract screening. A further 14 were removed after full text reading, with 18 articles finally included. Data were provided for 3,628 patients, including 1,535 DRFDs, 956 VLUs, and 791 PIs, with 164 microbial genera and 116 species identified using mNGS approaches. A high microbial diversity was observed depending on the geographical location and wound evolution. Clinically infected wounds were the most diverse, possibly due to a widespread colonisation by pathogenic bacteria from body and environmental microbiota. mNGS data identified the presence of virus (EBV) and fungi (Candida and Aspergillus species), as well as Staphylococcus and Pseudomonas bacteriophages. Conclusion: This study highlighted the benefit of mNGS for time-effective pathogen genome detection. Despite the majority of the included studies investigating only 16 S rDNA, ignoring a part of viral, fungal and parasite colonisation, mNGS detected a large number of bacteria through the included studies. Such technology could be implemented in routine microbiology for hard-to-heal wound microbiota investigation and post-treatment wound colonisation surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Evaluation of the Microbiome Identification of Forensically Relevant Biological Fluids: A Pilot Study
- Author
-
Gouello, Audrey, primary, Henry, Laura, additional, Chadli, Djamel, additional, Salipante, Florian, additional, Gibert, Joséphine, additional, Boutet-Dubois, Adeline, additional, and Lavigne, Jean-Philippe, additional
- Published
- 2024
- Full Text
- View/download PDF
9. Evolution of the urinary microbiota in spinal cord injury patients with decubitus ulcer: A snapshot study
- Author
-
Morsli, Madjid, primary, Salipante, Florian, additional, Gelis, Anthony, additional, Magnan, Chloé, additional, Guigon, Ghislaine, additional, Lavigne, Jean‐Philippe, additional, Sotto, Albert, additional, and Dunyach‐Remy, Catherine, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Correction: Usefulness of dynamic regression time series models for studying the relationship between antimicrobial consumption and bacterial antimicrobial resistance in hospitals: a systematic review.
- Author
-
Laffont-Lozes, Paul, Larcher, Romaric, Salipante, Florian, Leguelinel-Blache, Geraldine, Dunyach-Remy, Catherine, Lavigne, Jean-Philippe, Sotto, Albert, and Loubet, Paul
- Subjects
DRUG resistance in bacteria ,DRUG resistance in microorganisms ,TIME series analysis ,HOSPITALS ,INFECTION control - Abstract
This document is a correction notice for an article titled "Usefulness of dynamic regression time series models for studying the relationship between antimicrobial consumption and bacterial antimicrobial resistance in hospitals: a systematic review." The original article, published in Antimicrobial Resistance & Infection Control, mistakenly omitted rows below the 8th row of Table 1. The table has now been amended to include the complete information as intended. The correction notice is provided by the authors of the article, and the publisher, Springer Nature, remains neutral in terms of jurisdictional claims and institutional affiliations. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
11. Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens.
- Author
-
Plumet L, Costechareyre D, Lavigne J-P, Kissa K, and Molle V
- Abstract
The escalating prevalence of antibiotic-resistant bacterial infections necessitates urgent alternative therapeutic strategies. Phage therapy, which employs bacteriophages to specifically target pathogenic bacteria, emerges as a promising solution. This review examines the efficacy of phage therapy in zebrafish models, both embryos and adults, which are proven and reliable for simulating human infectious diseases. We synthesize findings from recent studies that utilized these models to assess phage treatments against various bacterial pathogens, including Enterococcus faecalis , Pseudomonas aeruginosa , Mycobacterium abscessus , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , and Escherichia coli . Methods of phage administration, such as circulation injection and bath immersion, are detailed alongside evaluations of survival rates and bacterial load reductions. Notably, combination therapies of phages with antibiotics show enhanced efficacy, as evidenced by improved survival rates and synergistic effects in reducing bacterial loads. We also discuss the transition from zebrafish embryos to adult models, emphasizing the increased complexity of immune responses. This review highlights the valuable contribution of the zebrafish model to advancing phage therapy research, particularly in the face of rising antibiotic resistance and the urgent need for alternative treatments.
- Published
- 2024
- Full Text
- View/download PDF
12. The zebrafish embryo model: unveiling its potential for investigating phage therapy against methicillin-resistant Staphylococcus aureus infection.
- Author
-
Plumet L, Magnan C, Ahmad-Mansour N, Sotto A, Lavigne J-P, Costechareyre D, Kissa K, and Molle V
- Subjects
- Animals, Disease Models, Animal, Embryo, Nonmammalian microbiology, Microbial Sensitivity Tests, Zebrafish microbiology, Methicillin-Resistant Staphylococcus aureus drug effects, Methicillin-Resistant Staphylococcus aureus virology, Phage Therapy methods, Vancomycin pharmacology, Vancomycin therapeutic use, Staphylococcal Infections therapy, Staphylococcal Infections microbiology, Staphylococcal Infections drug therapy, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use
- Abstract
Staphylococcus aureus is a pathogenic bacterium responsible for a broad spectrum of infections, including cutaneous, respiratory, osteoarticular, and systemic infections. It poses a significant clinical challenge due to its ability to develop antibiotic resistance. This resistance limits therapeutic options, increases the risk of severe complications, and underscores the urgent need for new strategies to address this threat, including the investigation of treatments complementary to antibiotics. The evaluation of novel antimicrobial agents often employs animal models, with the zebrafish embryo model being particularly interesting for studying host-pathogen interactions, establishing itself as a crucial tool in this field. For the first time, this study presents a zebrafish embryo model for the in vivo assessment of bacteriophage efficacy against S. aureus infection. A localized infection was induced by microinjecting either methicillin-resistant S. aureus (MRSA) or methicillin-susceptible S. aureus (MSSA). Subsequent treatments involved administering either bacteriophage, vancomycin (the reference antibiotic for MRSA), or a combination of both via the same route to explore potential synergistic effects. Our findings indicate that the bacteriophage was as effective as vancomycin in enhancing survival rates, whether used alone or in combination. Moreover, bacteriophage treatment appears to be even more effective in reducing the bacterial load in S. aureus -infected embryos post-treatment than the antibiotic. Our study validates the use of the zebrafish embryo model and highlights its potential as a valuable tool in assessing bacteriophage efficacy treatments in vivo ., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.